Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cutaneous necrotic ulceration due to BCG re-vaccination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  3. What you always needed to know about electroporation based DNA vaccines

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Personalized cancer immunotherapy based on infusion of T cells holds the promise to specifically target a patient's individual tumor. Accumulating evidence indicates that the T cells mediating these tumor regressions after cancer immunotherapies may primarily target patient-specific mutations expressed by the patients' tumors and that the presence of these "neo-antigen" specific T-cells may be related to a high number of mutations in the tumor. In melanoma, treatment with autologous tumor-infiltrating lymphocytes (TILs) can mediate durable complete responses. Previous trials investigating TIL therapy in solid tumors other than melanoma have shown limited success, however none of these early trials used current preparative chemotherapy regimens, and the methods for in vitro lymphocyte expansion have changed considerably. New advances and understandings in T cell based immunotherapies have stimulated the interest in developing this approach for other indications. Here, we summarize the early clinical data in the field of adoptive cell transfer therapy (ACT) using tumor-infiltrating lymphocytes for patients with renal cell carcinoma (RCC) and ovarian cancer (OC). In addition we describe the major advances in the characterization and application of TIL therapy for patients with RCC and OC.

TidsskriftHuman vaccines & immunotherapeutics
Udgave nummer12
Sider (fra-til)2790-5
Antal sider6
StatusUdgivet - 2 dec. 2015

ID: 45968371